Fructosamine measurement for diabetes mellitus diagnosis and monitoring: a systematic review and meta-analysis protocol

• Published in: BMJ open Vol. 5; no. 5; p. e007689
• Main Authors: Nansseu, Jobert Richie N, Fokom-Domgue, Joël, Noubiap, Jean Jacques N, Balti, Eric V, Sobngwi, Eugène, Kengne, André Pascal
• Format: Journal Article
• Language: English
• Published: England British Medical Journal Publishing Group 15.05.2015; BMJ Publishing Group LTD; BMJ Publishing Group
• Subjects: Accuracy; Bayes Theorem; Biomarkers - blood; Blood Glucose - analysis; Cardiovascular disease; Data collection; Diabetes and Endocrinology; diabetes mellitus; Diabetes Mellitus - diagnosis; diagnosis; Fructosamine - blood; fructosamine measurement; Gestational diabetes; Glucose; Glucose Tolerance Test; Glycated Hemoglobin - analysis; Human subjects; Humans; Meta-analysis; Meta-Analysis as Topic; Metabolism; monitoring; Predictive Value of Tests; Sensitivity and Specificity; Systematic review; Systematic Reviews as Topic; diagnosis; diabetes mellitus; monitoring; fructosamine measurement
• ISSN: 2044-6055; 2044-6055
• DOI: 10.1136/bmjopen-2015-007689

IntroductionFructosamine is a marker of glucose control reflecting the average glycaemic level over the preceding 2–3 weeks. Fructosamine has not gained as much popularity as glycated haemoglobin (HbA1c) for diabetes mellitus (DM) control monitoring, and the related underlying reasons remain unclear. We aim to search for and summarise available evidence on the accuracy of fructosamine measurements to diagnose and monitor DM.Methods and analysisThis systematic review will include randomised control trials, controlled before-and-after studies, time series designs, cohort studies, case–control studies and cross-sectional surveys reporting the diagnosis and/or monitoring of DM (type 1 DM, type 2 DM and gestational DM) with fructosamine compared with other measures of glycaemia (fasting glucose, oral glucose tolerance test, random glucose, HbA1c), without any language restriction. We will perform electronic searches in PubMed, Scopus and other databases, supplemented with manual searches. Articles published from 1 January 1980 to 30 June 2015 will be eligible for inclusion in this review. Two authors will independently screen, select studies, extract data and assess the risk of bias with discrepancies resolved by consensus. We will assess clinical heterogeneity by examining the types of interventions and outcomes in each study, and pool studies judged to be clinically homogeneous. We will also assess statistical heterogeneity using the χ2 test of homogeneity and quantify it using the I2 statistic. Absolute accuracy measures (sensitivity, specificity) will be pooled in a bivariate random-effects model, allowing for intersetting variability. Negative and positive predictive values will be computed for fructosamine, compared with another measure of glycaemia from the pooled estimates of sensitivity and specificity, using Bayes’ theorem.Ethics and disseminationThis systematic review will use data from published studies and does not require ethics approval. Findings will be published in a peer-reviewed journal and presented at scientific conferences.Trial registration numberPROSPERO (ID=CRD42015015930).